Evidence-based treatments for female pattern hair loss: A summary of a Cochrane systematic review

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 995-1010

  Van Zuuren, E J ^a   Fedorowicz, Z ^b   Carter, B ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMA INTERNATIONAL UNIVERSITY   (Bahrain)

^c BANGOR UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ESTRADIOL; ADENOSINE; ALCOHOL; CYPROTERONE ACETATE; CYSTINE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; FULVESTRANT; GESTODENE; MEDROXYPROGESTERONE ACETATE; MELATONIN; MILLET SEED EXTRACT; MINOXIDIL; MYRISTYL NICOTINATE; NICOTINIC ACID DERIVATIVE; OCTYL NICOTINATE; ORAL CONTRACEPTIVE AGENT; PANTOTHENATE CALCIUM; PLANT EXTRACT; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALOPECIA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FEMALE PATTERN HAIR LOSS; HAIR FOLLICLE; HAIR GROWTH; HAIR LOSS; HUMAN; POSTMENOPAUSE BLEEDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCALP PRURITUS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ALOPECIA; DATABASES, FACTUAL; EVIDENCE-BASED MEDICINE; FEMALE; HAIR; HUMANS; LASER THERAPY; MINOXIDIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84868207008     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11166.x     Document Type: Review

References (47)

1. Bienova M, Kucerova R, Fiuraskova M, et al. Androgenetic alopecia and current methods of treatment. Acta Dermatovenerol Alp Panonica Adriat 2005; 14: 5-8.
2. Gan DC, Sinclair RD,. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc 2005; 10: 184-9.
3. Hoffmann R, Happle R,. Current understanding of androgenetic alopecia. Part I: etiopathogenesis. Eur J Dermatol 2000; 10: 319-27.
4. Leavitt M,. Understanding and management of female pattern alopecia. Facial Plast Surg 2008; 24: 414-27.
5. Olsen EA,. Female pattern hair loss. J Am Acad Dermatol 2001; 45: S70-80.
6. Yip L, Rufaut N, Sinclair R,. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol 2011; 52: 81-8.
7. Trüeb RM,. Molecular mechanisms of androgenetic alopecia. Exp Gerontol 2002; 37: 981-90.
8. Dinh QQ, Sinclair R,. Female pattern hair loss: current treatment concepts. Clin Interv Aging 2007; 2: 189-99.
9. Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005; 52: 301-11.
10. Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011; 164: 5-15.
11. Olsen EA,. Female pattern hair loss. In: Hair Growth and Disorders (, Blume-Peytavi U, Tosti A, Whiting DA, Trüeb RM, eds). Berlin: Springer Verlag, 2008; 171-86.
12. Sinclair R, Wewerinke M, Jolley D,. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005; 152: 466-73.
13. Ludwig E,. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977; 97: 247-54.
14. Sinclair R, Jolley D, Mallari R, et al. The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. J Am Acad Dermatol 2004; 51: 189-99.
15. van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for female pattern hair loss. Cochrane Database Syst Rev 2012; 5: CD007628.
16. Dolte KS, Girman CJ, Hartmaier S, et al. Development of a health-related quality of life questionnaire for women with androgenetic alopecia. Clin Exp Dermatol 2000; 25: 637-42.
17. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available at: http://www.cochrane-handbook.org (last accessed 5 July 2012).
18. Treadwell JR, Tregear SJ, Reston JT, et al. A system for rating the stability and strength of medical evidence. BMC Med Res Methodol 2006; 6: 52.
19. Blume-Peytavi U, Kunte C, Krisp A, et al. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges 2007; 5: 391-5.
20. Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011; 65: 1126-34.
21. DeVillez RL, Jacobs JP, Szpunar CA, et al. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol 1994; 130: 303-7.
22. Jacobs JP, Szpunar CA, Warner ML,. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol 1993; 32: 758-62.
23. Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50: 541-53.
24. Olsen EA,. Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis 1991; 48: 243-8.
25. Price VH, Menefee E,. Quantitative estimation of hair growth. I. Androgenetic alopecia in women: effect of minoxidil. J Invest Dermatol 1990; 95: 683-7.
26. Tsuboi R, Tanaka T, Nishikawa T, et al. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Eur J Dermatol 2007; 17: 37-44.
27. Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002; 146: 992-9.
28. Whiting DA, Jacobson C,. Treatment of female androgenetic alopecia with minoxidil 2%. Int J Dermatol 1992; 31: 800-4.
29. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43: 768-76.
30. Carmina E, Lobo RA,. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003; 79: 91-5.
31. Ukşal Ü, Bayram F, Utaş S, et al. Comparison of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. J Eur Acad Dermatol Venereol 1999; 12: S238.
32. Whiting DA, Waldstreicher J, Sanchez M, et al. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc 1999; 4: 282-4.
33. Draelos ZD, Jacobson EL, Kim H, et al. A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. J Cosmet Dermatol 2005; 4: 258-61.
34. Fischer TW, Burmeister G, Schmidt HW, et al. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol 2004; 150: 341-5.
35. Gassmueller J, Hoffmann R, Webster A,. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. Br J Dermatol 2008; 158: 109-15.
36. Gehring W, Gloor M,. Use of the phototrichogram to assess the stimulation of hair growth-an in vitro study of women with androgenetic alopecia. Z Hautkr 2000; 75: 419-23.
37. Georgala S, Katoulis AC, Georgala C, et al. Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology 2004; 208: 178-9.
38. Minozzi M, Unfer V, Costabile L,. Alopecia androgenetica in post-menopausal women. G Ital Ostet Ginecol 1997; 19: 341-4.
39. Oura H, Iino M, Nakazawa Y, et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double-blind, randomized, placebo-controlled trial. J Dermatol 2008; 35: 763-7.
40. Policarpi F, Giorgini S, Farella V, et al. Effects of application of a pulsed electrostatic field in male and female androgenetic alopecia. Ann Ital Dermatol Clin Sperimentale 1993; 47: 227-32.
41. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
42. Schünemann H, Brozek J, Oxman A, (eds), The GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendation Version 3.2 [updated March 2009]. Available at: http://www.cc-ims.net/gradepro (last accessed 5 July 2012).
43. Biondo S, Sinclair R,. Quality of life in Australian women with female pattern hair loss. Open Dermatol J 2010; 4: 90-4.
44. Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9 (Suppl. 6): S1-57.
45. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
46. Barber BL, Kaufman KD, Kozloff RC, et al. A hair growth questionnaire for use in the evaluation of therapeutic effects in men. J Dermatolog Treat 1998; 9: 181-6.
47. Tajima M, Hamada C, Arai T, et al. Characteristic features of Japanese women's hair with aging and with progressing hair loss. J Dermatol Sci 2007; 45: 93-103.